Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Sponsor
Exelixis
Study ID
NCT07620574
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer
  • Colorectal Cancer
  • Differentiated Thyroid Cancer (DTC)
  • Extra-Pancreatic NET (epNET)
  • Hepatocellular Carcinoma (HCC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Pancreatic Neuroendocrine Tumors (pNET)
  • Prostate Cancer
  • Renal Cell Carcinoma (RCC)

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    Administered as specified in the parent study.
  • Zanzalintinib — DRUG
    Administered as specified in the parent study.
  • Atezolizumab — DRUG
    Administered as specified in the parent study.
  • Nivolumab — DRUG
    Administered as specified in the parent study.
  • Abiraterone — DRUG
    Administered as specified in the parent study.
  • Prednisone — DRUG
    Administered as specified in the parent study.
  • Enzalutamide — DRUG
    Administered as specified in the parent study.

Study Details

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.

Key Dates

Start date
May 31, 2026
Status verified
May 2026
Primary completion
May 31, 2030
Completion
May 31, 2030

Study Design

Enrollment
5,000 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib/Zanzalintinib
    Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator.

Primary Outcome Measure

Number of Participants With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first) ]

Central Contacts

  • Exelixis Clinical Trials
    1-888-EXELIXIS (888-393-5494)
    [email protected]
  • Backup or International
    650-837-7400

Related Studies